
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is a promising company that has a positive outlook from a financial analyst's perspective. The company has a strong focus on developing cutting-edge, one-time gene therapies targeting the critical underlying pathology of neurodegenerative diseases. With a single reportable segment and a promising pipeline, including PBFT02, Passage Bio is positioned for both short-term and long-term success. Its recent increase in investments and accretion of premiums also points towards confidence in the company's future.
Bears say
Passage Bio is a clinical-stage genetic medicines company with a robust pipeline and strong biomarker data for its lead programs, creating excitement and potential for future clinical benefit. However, significant resources and time are needed for a randomized and controlled trial, which could be challenging to secure given the current financing environment and the lack of available treatment options for the target market. As a result, the negative outlook is based on the potential for financing risks and delays in clinical development.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares